Patent details

EP1476185 Title: ANTIBODIES TO CD40

Basic Information

Publication number:
EP1476185
PCT Application Number:
PCT/US/2002/036107
Type:
European Patent Granted for LU
Legal Status:
Expired
Application number:
EP028028983
PCT Publication Number:
WO/2003/040170
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
ANTIBODIES TO CD40
French Title of Invention:
ANTICORPS ANTI-CD40
German Title of Invention:
ANTIKÖRPER GEGEN CD40
SPC Number:

Dates

Filing date:
08/11/2002
Grant date:
31/07/2013
EP Publication Date:
31/07/2013
PCT Publication Date:
15/05/2003
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
17/11/2004
EP B1 Publication Date:
31/07/2013
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
08/11/2022
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
08/11/2002
 
 

Name:
Amgen Fremont Inc.
Address:
One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States (US)

Name:
Pfizer Products Inc.
Address:
Eastern Point Road, Groton, CT 06340, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
11/09/2013
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
BEDIAN Vahe
Address:
United States (US)

2

Name:
GLADUE Ronald, P.
Address:
United States (US)

3

Name:
FENG Xiao
Address:
United States (US)

4

Name:
JIA Xiao-Chi
Address:
United States (US)

5

Name:
CORVALAN Jose
Address:
United States (US)

Priority

Priority Number:
348980 P
Priority Date:
09/11/2001
Priority Country:
United States (US)

Classification

Main IPC Class:
A61K 39/395;

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
25/10/2021
Last Annual Fee Paid Number:
20
Last Annual Fee Paid Amount:
300 Euro
Payer:
CPA GLOBAL THE IP PLATFORM
Filing date Document type Number of pages